Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies

Imagem de Miniatura
Arquivos
art_SOUZA_Intravenous_human_immunoglobulin_andor_methylprednisolone_pulse_therapies_as_2019.PDF (686.05 KB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
Citação
RHEUMATOLOGY INTERNATIONAL, v.39, n.7, p.1201-1212, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
To evaluate the relevance of immunoglobulin (IVIg) and/or methylprednisolone pulse therapies in immune-mediated necrotizing myopathy (IMNM). Secondarily, to analyze the muscle damage measured by late magnetic resonance images (MRI). This retrospective study included 13 patients with defined IMNM (nine patients positive for the anti-signal recognition particle and four patients positive for hydroxyl-methyl-glutaryl coenzyme A reductase) who were followed from 2012 to 2018. International Myositis Assessment and Clinical Studies Group (IMACS) scoringassessed the response to a standardized treat-to-target protocol with disease activity core-set measures and late magnetic resonance imaging (MRI). The patients had a mean age of 53.5years and were predominantly female and of white ethnicity. Median symptom and mean follow-up durations were 4 and 39 months, respectively. All patients received IVIg and/or methylprednisolone pulse therapies. All IMACS core-set measurements improved significantly after initial treatment. Nine patients achieved complete clinical response and among them 2 had complete remission. Eleven patients had discontinued glucocorticoid use by the end of the study. Only 2 patients had moderate muscle atrophy or fat replacement observed by MRI, with the remainder presenting normal or mild findings. Our patients with IMNM treated with an aggressive immunosuppressant therapy had a marked improvement in all IMACS core-set domains. Moreover, the MRI findings suggest that an early treat-to-target approach could reduce the odds of long-term muscle disability. Methylprednisolone and/or IVIg pulse therapies aiming at a target of complete clinical response are potential treatment strategies for IMNM that should be studied in future prospective studies.
Palavras-chave
Glucocorticoids, Intravenous human immunoglobulin, Magnetic resonance, Methylprednisolone, Necrotizing myopathies
URI
https://observatorio.fm.usp.br/handle/OPI/32987
Referências
  1. Aggarwal R, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2017-211400
  2. BALLOW M, 1930, CANCER S, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+
  3. Basharat P, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0548-6
  4. BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387
  5. Bronner IM, 2003, J NEUROL, V250, P480, DOI 10.1007/s00415-003-1027-y
  6. Bruce B, 2003, J RHEUMATOL, V30, P167
  7. Carroll MB, 2016, JCR-J CLIN RHEUMATOL, V22, P376, DOI 10.1097/RHU.0000000000000427
  8. Christopher-Stine L, 2010, ARTHRITIS RHEUM-US, V62, P2757, DOI 10.1002/art.27572
  9. Dalakas MC, 2011, NEUROPATH APPL NEURO, V37, P226, DOI 10.1111/j.1365-2990.2010.01153.x
  10. Dalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225
  11. DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704
  12. de Souza FHC, 2017, CLIN EXP RHEUMATOL, V35, P766
  13. DWYER JM, 1992, NEW ENGL J MED, V326, P107
  14. FRIES JF, 1982, J RHEUMATOL, V9, P789
  15. Grable-Esposito P, 2010, MUSCLE NERVE, V41, P185, DOI 10.1002/mus.21486
  16. Hengstman GJD, 2006, ANN RHEUM DIS, V65, P1635, DOI 10.1136/ard.2006.052191
  17. Isenberg DA, 2004, RHEUMATOLOGY, V43, P49, DOI 10.1093/rheumatology/keg427
  18. Kao AH, 2004, ARTHRITIS RHEUM, V50, P209, DOI 10.1002/art.11484
  19. Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468
  20. Mammen AL, 2015, NEW ENGL J MED, V373, P1680, DOI 10.1056/NEJMc1506163
  21. Mammen AL, 2012, ARTHRIT CARE RES, V64, P269, DOI 10.1002/acr.20662
  22. Miller T, 2002, J NEUROL NEUROSUR PS, V73, P420, DOI 10.1136/jnnp.73.4.420
  23. Oddis CV, 2005, ARTHRITIS RHEUM, V52, P2607, DOI 10.1002/art.21291
  24. Pestronk A, 2011, CURR OPIN RHEUMATOL, V23, P595, DOI 10.1097/BOR.0b013e32834bab42
  25. Cruellas MGP, 2013, CLINICS, V68, P909, DOI 10.6061/clinics/2013(07)04
  26. Pinal-Fernandez I, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210198
  27. Preusse C, 2012, AM J PATHOL, V181, P2161, DOI 10.1016/j.ajpath.2012.08.033
  28. Rider LG, 2010, ARTHRIT CARE RES, V62, P465, DOI 10.1002/acr.20035
  29. Suzuki S, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0277-y
  30. Zheng YM, 2015, RHEUMATOLOGY, V54, P1017, DOI 10.1093/rheumatology/keu422

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17